BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22393418)

  • 1. Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells.
    Jia L; Gopinathan G; Sukumar JT; Gribben JG
    PLoS One; 2012; 7(2):e32584. PubMed ID: 22393418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
    Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
    Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
    Hideshima T; Ikeda H; Chauhan D; Okawa Y; Raje N; Podar K; Mitsiades C; Munshi NC; Richardson PG; Carrasco RD; Anderson KC
    Blood; 2009 Jul; 114(5):1046-52. PubMed ID: 19436050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.
    Juvekar A; Manna S; Ramaswami S; Chang TP; Vu HY; Ghosh CC; Celiker MY; Vancurova I
    Mol Cancer Res; 2011 Feb; 9(2):183-94. PubMed ID: 21224428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
    Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
    Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
    Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
    Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
    Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
    Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-kappaB and activator protein-1 related mechanisms.
    Chen Z; Ricker JL; Malhotra PS; Nottingham L; Bagain L; Lee TL; Yeh NT; Van Waes C
    Mol Cancer Ther; 2008 Jul; 7(7):1949-60. PubMed ID: 18645005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term incubation with proteasome inhibitors (PIs) induces IκBα degradation via the lysosomal pathway in an IκB kinase (IKK)-dependent and IKK-independent manner.
    Lee KH; Jeong J; Yoo CG
    J Biol Chem; 2013 Nov; 288(45):32777-32786. PubMed ID: 24085292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
    Hideshima H; Yoshida Y; Ikeda H; Hide M; Iwasaki A; Anderson KC; Hideshima T
    Int J Oncol; 2014 Apr; 44(4):1171-6. PubMed ID: 24481412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation.
    Li C; Chen S; Yue P; Deng X; Lonial S; Khuri FR; Sun SY
    J Biol Chem; 2010 May; 285(21):16096-104. PubMed ID: 20335171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
    Carew JS; Medina EC; Esquivel JA; Mahalingam D; Swords R; Kelly K; Zhang H; Huang P; Mita AC; Mita MM; Giles FJ; Nawrocki ST
    J Cell Mol Med; 2010 Oct; 14(10):2448-59. PubMed ID: 19583815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
    Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
    Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
    Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
    Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation.
    Parcellier A; Schmitt E; Gurbuxani S; Seigneurin-Berny D; Pance A; Chantôme A; Plenchette S; Khochbin S; Solary E; Garrido C
    Mol Cell Biol; 2003 Aug; 23(16):5790-802. PubMed ID: 12897149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.
    Berenson JR; Ma HM; Vescio R
    Semin Oncol; 2001 Dec; 28(6):626-33. PubMed ID: 11740821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maximal apoptosis of renal cell carcinoma by the proteasome inhibitor bortezomib is nuclear factor-kappaB dependent.
    An J; Sun Y; Fisher M; Rettig MB
    Mol Cancer Ther; 2004 Jun; 3(6):727-36. PubMed ID: 15210859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle.
    Wyke SM; Tisdale MJ
    Br J Cancer; 2005 Feb; 92(4):711-21. PubMed ID: 15714207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.